Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Growth kinetics of SARS-coronavirus in Vero E6 cells

Els Keyaerts a, Leen Vijgen a, Piet Maes a, Johan Neyts b, Marc Van Ranst a,c,*

a Laboratory of Clinical and Epidemiological Virology, Department of Microbiology and Immunology, Rega Institute for Medical Research, University of Leuven, Belgium

b Laboratory of Virology and Chemotherapy, Department of Microbiology and Immunology, Rega Institute for Medical Research, University of Leuven, Belgium

c Laboratory of Clinical Virology, University Hospital Gasthuisberg, University of Leuven, Belgium

Received 2 February 2005

Abstract

Vero E6 cells are commonly used for in vitro studies of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) and for antiviral evaluation purposes. A better understanding of the SARS-CoV growth kinetics in Vero E6 cells is crucial to help elucidate the mechanism of antiviral activity of selective antiviral agents. In this study, the growth kinetics of SARS-CoV in Vero E6 cells were studied by quantitation of intra- and extracellular viral RNA load as well as extracellular virus yield at different time points post-infection. At 12 h post-infection, the intracellular viral RNA load was $3 \times 10^2$-fold higher than at the time of infection, and the extracellular viral RNA load was increased with a factor of $2 \times 10^3$. Intracellular viral RNA levels started to rise at 6 h post-infection. One hour later (at 7 h post-infection), the levels of extracellular SARS-CoV RNA also began to rise. This was corroborated by the fact that infectious progeny SARS-CoV also first appeared in the supernatant between 6 and 7 h post-infection. At 12 h post-infection, SARS-CoV reached titers in the supernatant of $5.2 \times 10^3$ CCID$_{50}$/ml.

© 2005 Elsevier Inc. All rights reserved.

Keywords: SARS-CoV; Severe acute respiratory syndrome; Coronavirus; Growth kinetics; Replication cycle; Real-time PCR; Vero E6 cells

Severe acute respiratory syndrome (SARS) recently emerged as a new highly contagious human disease [1]. A novel member of the Coronaviridae family has been identified as the causative agent of SARS [2–6]. To date, 5 human coronaviruses (HCoV) are known: HCoV-OC43, HCoV-229E, HCoV-NL63, the recently identified HCoV-HKU1, and SARS-coronavirus (SARS-CoV) [7,8]. Coronaviruses are classified in three groups based on genetic and serological relationships [9]. It has been suggested that SARS-CoV is the first member of a fourth group of coronaviruses or an outlier of group 2 [10,11]. Coronaviruses are large, irregularly shaped, enveloped viruses with a diameter of 60–220 nm. The envelope glycoproteins have a characteristic crown- or halo-like appearance. The genomes of coronaviruses range in length from 27 to 32 kb, the largest of all RNA viruses. The SARS-CoV genome contains 5 major open reading frames, encoding the replicase polyprotein, the spike glycoprotein (S), the envelope protein (E), the membrane glycoprotein (M), and the nucleocapsid protein (N). In addition to these proteins, the SARS-CoV genome also codes for other uncharacterized structural and non-structural proteins [6,10]. Coronavirus RNA synthesis occurs in the cytoplasm via negative-strand RNA intermediates. In analogy to other coronaviruses, SARS-CoV has a polycistronic genome organization and synthesizes multiple subgenomic mRNAs, all overlapping at the 3′ end and all containing the same 5′ leader sequence, derived from the 5′ end of the genome [12].

SARS-CoV produces cytopathic effects (CPE) in Vero E6 cells, providing a simple model for in vitro
antiviral evaluation [13]. A number of antiviral compounds have been shown to be effective against SARS-CoV: interferon α, β, and γ, chloroquine (an old antimalarial drug), glycyrrhizin (an active component of liquorice roots), nielasamide (an antihelminthic drug), nelfinavir (an HIV protease inhibitor), and SNAP (a nitric oxide donor) [14–21].

In order to elucidate the mechanism of action of antiviral compounds, a better comprehension of the SARS-CoV replication cycle in cell culture is crucial. Apart from electron microscopic data, little is known about the kinetics of SARS-CoV infection in cell culture. No conclusive information regarding the duration of one replication cycle is available. Using electron microscopy, one research group distinguished virus particles 24 h post-infection. A second group identified progeny virus as early as 5 h post-infection and discovered that the SARS-coronavirus attached, entered, and uncoated its nucleocapsids, all within a 30-min period [13,22–24]. For other coronaviruses, the time of one in vitro replication cycle is reported to be relatively short, about 6–8 h [25].

We here examine the growth kinetics of the SARS-CoV Frankfurt 1 strain in Vero E6 cells by determining the infectious virus titer and by quantifying intra- and extracellular viral RNA load at various time points post-infection.

**Materials and methods**

*Cells and virus.* The SARS-CoV Frankfurt 1 strain was kindly provided by Prof. Dr. H.F. Rabenau from the Johann Wolfgang Goethe University, Frankfurt, Germany. Vero E6 cells were propagated at 37 °C in 5% CO₂ in minimal essential medium (MEM; Gibco, Life Technologies, Rockville, MD) supplemented with 10% fetal calf serum (FCS; Integro, Zaandam, The Netherlands), 1% l-glutamine (Gibco, Life Technologies, Rockville, MD), and 1.4% sodium bicarbonate (Gibco, Life Technologies, Rockville, MD). Virus-infected cells were maintained at 37 °C in 5% CO₂ in MEM supplemented with 2% FCS.

*Real-time quantitative RT-PCR.* The methodology of the real-time RT-PCR assay has been described previously [26]. Briefly, a real-time quantitative RT-PCR was designed in the nsp11 region of the replicase 1B domain of the SARS-CoV genome. A 25 μL RT-PCR was carried out using 5 μL of extracted RNA or standard cRNA, 12.5 μL one-step RT qPCR Mastermix containing ROX as a passive reference (Eurogentec, Seraing, Belgium), 900 nM forward and reverse primers, and 150 nM minor groove binding probe. Amplification and detection were performed in an ABI PRISM 7700 Sequence Detection System (Applied Biosystems, Foster City, CA, USA) under the following conditions: an initial reverse transcription at 48 °C for 30 min, followed by PCR activation at 95 °C for 10 min and 45 cycles of amplification (15 s at 95 °C and 1 min at 60 °C). During amplification, the ABI PRISM sequence detector monitored real-time PCR amplification by quantitative analysis of fluorescence emissions. The reporter dye (FAM) signal was measured against the internal reference dye (ROX) signal to normalize for non-PCR-related fluorescence fluctuations occurring from well to well. The threshold cycle represented the refraction cycle number at which a positive amplification was measured, and was set at 10 times the standard deviation of the mean baseline emission calculated for PCR cycles 3–15.

*Extracellular and intracellular viral RNA quantitation.* One hundred CCID₅₀ (50% cell culture infectious dose) SARS-CoV was allowed to adsorb at 37 °C for 20 min on Vero E6 cells in 24-well culture plates, containing 10⁵ cells and 400 μL MEM 2%. Subsequently, the cells were washed 5 times with PBS. At different time points post-infection, supernatants putatively containing free viruses and infected cells were collected. Viral RNA was isolated from the supernatant and total RNA was isolated from the infected cells, using the QIAamp viral RNA minikit (Qiagen) and the RNeasy minikit (Qiagen), respectively. The samples were tested by quantitative RT-PCR for the presence and quantitation of viral RNA. The 18S Genomic Endogenous Control Kit (Eurogentec, Seraing, Belgium) was used for normalization of the intracellular quantitative RT-PCR analysis by determining the number of collected Vero E6 cells.

*Virus yield assay.* One hundred CCID₅₀ SARS-CoV was allowed to adsorb at 37 °C for 20 min on Vero E6 cells. The inoculum was removed, and the cells were washed 5 times with PBS. At different time points, cell culture supernatant putatively containing free viruses was collected. The yield of infectious viral particles was determined using a CCID₅₀ assay where virus titers are determined by visual scored CPE, using 10-fold dilution steps. The limiting dilution end point (CCID₅₀/ml) was determined by the Karber equation, where CCID₅₀/ml = 10^L·a·b; in which L is the lowest dilution, d is the logarithm of the dilution factor (d = 1 for the 10-fold serial dilution), S is the sum of proportions of infection-positive wells per total wells at each subsequent dilution, and V is the volume (ml) of the diluted virus used for inoculation [27].

*Statistics.* The statistical significances of the rise of intracellular and extracellular viral RNA load were assessed by using a two-tailed Student’s t test.

**Results and discussion**

Confluent Vero E6 cells grown in a 24-well culture plate were incubated with 100 CCID₅₀ SARS-CoV (which corresponds to 8.5 × 10⁷ SARS-CoV genome copies) for 20 min. Intracellular levels of viral RNA were determined by quantitative RT-PCR every 30 min between 1 and 5 h post-infection and every 60 min between 6 and 12 h post-infection (Fig. 1A). At least 4 replicate experiments were performed to determine the intracellular amount of viral RNA copies. After washing the Vero E6 cells 5 times with PBS, a remaining background of 3.4 × 10⁴ copies per 10⁶ cells was detected. From 1 to 5 h post-infection, the intracellular viral load remained nearly constant. A statistical significant (P < 0.05) increase in the number of intracellular RNA copies was first observed at 6 h post-infection. After this initial amplification, the titer of the intracellular viral RNA increased exponentially, reaching a titer of 9.6 × 10⁶ RNA copies per 10⁶ cells at 12 h post-infection.

Extracellular levels of viral RNA in the cell supernatant were determined every 60 min by means of quantitative RT-PCR from 1 to 12 h post-infection (Fig. 1B). Extracellular viral load quantitation was performed in at least 9 replicates. After washing the Vero E6 cells 5 times with PBS, the remaining background was determined to be 1.5 × 10⁴ RNA copies/ml. From 1 to 6 h
post-infection, the extracellular viral load remained nearly constant. A significant ($P < 0.0001$) increase in the number of extracellular viral RNA copies, i.e., a nearly 10-fold increase in viral RNA load from $4.0 \times 10^4$ to $2.8 \times 10^5$ genome equivalents/ml, was observed 7 h post-infection. After this initial extracellular raise, the viral RNA in the supernatant continued to increase, reaching viral RNA titers as high as $1.1 \times 10^7$ copies/ml at 12 h post-infection.

Measuring viral RNA does not imply the presence of live virus. For this purpose, we determined the infectious viral titer of the supernatant collected at different time points post-infection (Fig. 2). During the first 5 h, no infectious virus could be detected in the culture supernatant. Infectious progeny SARS-CoV first appeared in the supernatant 6 h post-infection at a low titer ($2.1 \times 10^1$ CCID$_{50}$/ml), and a larger proportion of infectious progeny virus appeared at 7 h post-infection, at a titer of $5.2 \times 10^2$ CCID$_{50}$/ml. By 12 h post-infection, Vero E6 cells infected with SARS-CoV had produced an infectious virus titer of $5.2 \times 10^3$ CCID$_{50}$/ml.

Our aim was to determine the kinetics and the length of one viral cycle of SARS-CoV in Vero E6 cells. Our observations suggest that one replication cycle of the SARS-CoV takes 7 h to complete and that onset of intracellular RNA replication is at 6 h post-infection. When comparing the absolute increase of copies, we see that the difference between the initial viral RNA load and the viral load 12 h after infection is more definite extracellular than intracellular. Intracellular we distinguish a $3 \times 10^2$-fold increase, while in extracellular a growth of $2 \times 10^3$-fold is observed.

When elucidating the mechanism of antiviral action of a particular antiviral compound, it is often important to be able to carry out so-called time-of-drug-addition assays. This time-of-drug-addition assay allows one to obtain a first rough idea about the step in the replication cycle at which the compound exerts its antiviral activity. Besides electron microscopic based information, no data about the growth of SARS-CoV in Vero E6 cells were
available. Our results provide further insights into the SARS-CoV replication cycle. An antiviral compound, which remains its antiviral activity at a time point of 6 h post-infection or later, is not likely to interfere with the attachment, penetration or replication of the genomic RNA, but rather with the processing of viral proteins, assembly or release of the virions.

Acknowledgments

We thank the colleagues of the laboratory of Clinical and Epidemiological Virology, Department of Microbiology and Immunology, Rega Institute for Medical Research, University of Leuven, Belgium, for helpful comments and discussion. This work was supported by a fellowship of the Flemish Fonds voor Wetenschappelijk Onderzoek (FWO) to Leen Vijgen, and by FWO-Grant G.0288.01.

References

[1] J.S. Peiris, Y. Guan, K.Y. Yuen, Severe acute respiratory syndrome, Nat. Med. 10 (2004) 88-97.
[2] C. Drosten, S. Gunther, W. Preiser, S. van der Werf, H.R. Brodt, S. Becker, H. Rabenau, M. Panning, L. Kolesnikova, R.A. Fouchier, A. Berger, A.M. Burguiere, J. Cinatl, M. Eickmann, N. Esc riou, K. Grywna, S. Kramme, J.C. Manuguerra, S. Muller, V. Rickerts, M. Sturmer, S. Vie th, H.D. Klenk, A.D. Osterhaus, H. Schmitz, H.W. Doerr, Identification of a novel coronavirus in patients with severe acute respiratory syndrome, N. Engl. J. Med. 348 (2003) 1967–1976.
[3] T.G. Kisazek, D. Erdman, C.S. Goldsmith, S.R. Zaki, T. Peret, S. Emery, S. Tong, C. Urbani, J.A. Comer, W. Lim, P.E. Rollin, S.F. Dowell, A.E. Ling, C.D. Humphrey, W.J. Shieh, J. Guarnier, C.D. Paddock, P. Rota, B. Fields, J. DeRisi, J.Y. Yang, N. Cox, J.M. Hughes, J.W. LeDuc, W. Preiser, S. van der Werf, N. Escriou, K. Grywna, S. Kramme, J.C. Manuguerra, S. Muller, V. Rickerts, M. Sturmer, S. Vie th, H.D. Klenk, A.D. Osterhaus, H. Schmitz, H.W. Doerr, Identification of a novel coronavirus in patients with severe acute respiratory syndrome, N. Engl. J. Med. 348 (2003) 1967–1976.
[4] T. Kuiket, R.A. Fouchier, M. Schutten, G.F. Rimmelziaan, G. van Amerongen, D. van Riel, J.D. Laman, T. de Jong, G. van Doornnum, W. Lim, A.E. Ling, P.K. Chan, J.S. Tam, M.C. Zambon, R. Gopal, C. Drosten, S. van der Werf, N. Escriou, J.C. Manuguerra, K. Stohr, J.S. Peiris, A.D. Osterhaus, Newly discovered coronavirus as the prime cause of severe acute respiratory syndrome, Lancet 362 (2003) 263–270.
[5] J.S. Peiris, S.T. Lai, L.L. Poon, Y. Guan, L.Y. Yam, W. Lim, J. Nicholls, W.K. Yee, W.W. Yan, M.T. Cheung, V.C. Cheng, K.H. Chan, D.N. Tsang, R.W. Yung, T.K. Ng, K.Y. Yuen, Coronavirus as a possible cause of severe acute respiratory syndrome, Lancet 361 (2003) 1319–1325.
[6] P.A. Rota, M.S. Oberste, S.S. Monroe, W.A. Nix, R. Campagnoli, J.P. Ennogle, S. Penaranda, B. Bankamp, K. Maher, M.-H. Chen, S. Tong, A. Tamin, L. Mace, F. Frace, J.L. Derisi, Q. Chen, D. Wang, D.D. Erdman, T.C.T. Peret, C. Burns, T.G. Kisazek, P.E. Rollin, A. Sanchez, S. Liflick, B. Holloway, J. Limor, K. McCausland, M. Olsen-Rasmussen, R. Fouchier, S. Gunther, A.D.M.E. Osterhaus, C. Drosten, M.A. Pallansch, L.J. Anderson, W.J. Bellini, Characterization of a novel coronavirus associated with severe acute respiratory syndrome, Science 300 (2003) 1394–1399.
[7] L. van der Hoek, K. Pyrc, M.F. Jebbink, W. Vermeulen-Oost, R.J.M. Berkhour, K.C.L. Wolthers, P.M.E. Wertheim-van Dillen, J. Kaandorp, J. Spaargaren, B. Berkhour, Identification of a new human coronavirus, Nat. Med. 10 (2004) 368–373.
[8] P.C. Woo, S.K. Lau, C.M. Chu, K.H. Chan, H.W. Tsui, Y. Huang, B.H. Wong, R.W. Poon, J.J. Cai, W.L. Poon, S.S. Wong, Y. Guan, J.S. Peiris, K.Y. Yuen, Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia, J. Virol. 79 (2005) 884–895.
[9] J.M. Gonzalez, P. Gomez-Puertas, D. Cavanagh, A.E. Gorbalenya, L. Enjuanes, A comparative sequence analysis to revise the current taxonomy of the family Coronaviridae, Arch. Virol. 148 (2003) 2207–2235.
[10] M.A. Marra, S.J.M. Jones, C.R. Astell, R.A. Holt, A. Brooks-Wilson, Y.S.N. Butterfield, J. Khattra, J.K. Asano, S.A. Barber, S.Y. Chan, A. Cloutier, S.M. Coughlin, D. Freeman, N. Girn, O.L. Griffith, S.R. Leach, M. Mayo, H. McDonald, S.B. Montgomery, P.K. Pando, A.S. Petrescu, G. Robertson, J.E. Schein, A. Siddiqui, D.E. Smallus, J.M. Stott, G.S. Yang, F. Plummer, A. Andonov, H. Artsob, N. Bastien, K. Bernard, T.F. Booth, D. Bowness, M. Czub, M. Drebolt, L. Fernando, R. Flick, M. Garbutt, M. Gray, A. Grolla, S. Jones, H. Feldmann, A. Meyers, A. Kabani, Y. Li, S. Normand, U. Stroher, G.A. Tipples, S. Tyler, R. Voigri, D. Ward, B. Watson, R.C. Brunham, M. Krajden, M. Petric, D. Skowronski, C. Upton, R. Roper, The Genome sequence of the SARS-associated coronavirus, Science 300 (2003) 1399–1404.
[11] E.J. Snijder, P.J. Breidenbeck, J.C. Dobbe, V. Thiel, J. Ziebuhr, L.L. Poon, Y. Guan, M. Rozanov, W.J. Spaan, A.E. Gorbalenya, Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage, J. Mol. Biol. 331 (2003) 991–1004.
[12] J. Ziebuhr, Molecular biology of severe acute respiratory syndrome coronavirus, Curr. Opin. Microbiol. 7 (2004) 412–419.
[13] M.L. Ng, S.H. Tan, E.E. See, E.E. Ooi, A.E. Ling, Proliferative growth of SARS coronavirus in Vero E6 cells, J. Gen. Virol. 84 (2003) 3291–3303.
[14] J. Cinatl, B. Morgenstern, G. Bauer, P. Chandra, H. Rabenau, H.W. Doerr, Treatment of SARS with human interferons, Lancet 362 (2003) 293–294.
[15] B. Sainz Jr., E.C. Mossel, C.J. Peters, R.F. Garry, Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV), Virology 329 (2004) 11–17.
[16] B. Morgenstern, M. Michaelis, P.C. Baer, H.W. Doerr, J. Cinatl, Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines, Biochem. Biophys. Res. Commun. 326 (2005) 905–908.
[17] E. Keyaerts, L. Vijgen, P. Maes, J. Neyts, M. Van Ranst, In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine, Biochem. Biophys. Res. Commun. 323 (2004) 264–268.
[18] J. Cinatl, B. Morgenstern, G. Bauer, P. Chandra, H. Rabenau, H.W. Doerr, Glycyrrhizin, an active component of liquorice roots, and replication of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage, J. Mol. Biol. 331 (2003) 991–1004.
[19] C.J. Wu, J.T. Jan, C.M. Chen, H.P. Hsieh, D.R. Hwang, H.W. Huang, B.H. Wong, R.W. Poon, J.J. Cai, W.L. Poon, S.S. Wong, Y. Guan, J.S. Peiris, K.Y. Yuen, Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia, J. Virol. 79 (2005) 884–895.
[20] N. Yamamoto, R. Yang, Y. Yoshinaka, S. Amari, T. Nakano, J. Cinatl, H. Rabenau, H.W. Doerr, G. Hunsmann, A. Otaka, H. Tamamura, N. Fujii, N. Yamamoto, HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus, Biochem. Biophys. Res. Commun. 318 (2004) 719–725.
[21] E. Keyaerts, L. Vijgen, L. Chen, P. Maes, G. Hedenstierna, M. Van Ranst, Inhibition of SARS-coronavirus infection in vitro by S-nitroso-N-acetylpenicillamine, a nitric oxide donor compound, Int. J. Infect. Dis. 8 (2004) 223–226.

[22] M.L. Ng, S.H. Tan, E.E. See, E.E. Ooi, A.E. Ling, Early events of SARS coronavirus infection in vero cells, J. Med. Virol. 71 (2003) 323–331.

[23] Z. Qinfen, C. Jinming, H. Xiaojun, Z. Huanying, H. Jicheng, F. Ling, L. Kunpeng, Z. Jingqiang, The life cycle of SARS coronavirus in Vero E6 cells, J. Med. Virol. 73 (2004) 332–337.

[24] M.L. Ng, Topographic changes in SARS coronavirus-infected cells at late stages of infection, Emerg. Infect. Dis. 10 (2004) 1907–1914.

[25] L.S. Sturman, K.K. Takemoto, Enhanced growth of a murine coronavirus in transformed mouse cells, Infect. Immun. 6 (1972) 501–507.

[26] E. Keyaerts, L. Vijgen, P. Maes, J. Neyts, M. Van Ranst, Viral load quantitation of SARS-coronavirus RNA using a one-step real-time RT-PCR, Int. J. Infect. Dis. (2005), in press.

[27] G. Karber, Beitrag zur kollektiven behandlungpharmakologischer reihenversuche, Arch. Exp. Pathol. Pharmakol. 162 (1931) 480–483.